(Redirected from Scatena R)
|News and Events||Working Groups||Short-Term Scientific Missions||Management Committee||Members|
COST Action CA15203 (2016-2021): MitoEAGLE
Evolution-Age-Gender-Lifestyle-Environment: mitochondrial fitness mapping
MitoPedia topics: EAGLE
COST: Member COST WG1: WG1 COST WG2: WG2 COST WG3: WG3 COST WG4: WG4 COST Mentor: Mentor
|Name||Scatena Roberto, Prof. PhD|
Institute of Biochemistry and Clinical Biochemistry,
Polyclinic A. Gemelli - Catholic University, IT
|Address||Largo A. Gemelli 8, 00168|
|O2k-Network Lab||IT Rome Scatena R|
New Open Access Journal
- Dr. R. Scatena is the editor of 'Cancer Stem Cells'.
Labels: Field of research: Basic
|BEC 2020.1 doi10.26124bec2020-0001.v1||2020||Gnaiger E et al ― MitoEAGLE Task Group (2020) Mitochondrial physiology. https://doi.org/10.26124/bec:2020-0001.v1|
|Bottoni 2019 Adv Exp Med Biol||2019||Bottoni P, Scatena R (2019) Mitochondrial metabolism in cancer. A tangled topic. Which role for proteomics? Adv Exp Med Biol 1158:1-16.|
|Scatena 2019 Curr Med Chem||2019||Scatena R, Bottoni P (2019) The tangled mitochondrial metabolism in cancer: An innovative pharmacological approach. Curr Med Chem 27:2106-17.|
|Tesori 2015 Sci Rep||2015||Tesori V, Piscaglia AC, Samengo D, Barba M, Bernardini C, Scatena R, Pontoglio A, Castellini L, Spelbrink JN, Maulucci G, Puglisi MA, Pani G, Gasbarrini A (2015) The multikinase inhibitor Sorafenib enhances glycolysis and synergizes with glycolysis blockade for cancer cell killing. Sci Rep 5:9149.|
|Scatena 2012 Adv Exp Med Biol||2012||Scatena R, Bottoni P, Giardina B (eds) (2012) Advances in mitochondrial medicine. Adv Exp Med Biol 942:p461.|
|Scatena 2018 MiP2018||2018|
|Scatena 2017 Abstract MITOEAGLE Barcelona||2017|
|Scatena 2017 MITOEAGLE Obergurgl||2017|
- Specifically, we are studying mitochondrial metabolism in cancer cells. At this aim we are also participating to mt-HPP project, an Italian consortium whose target is a definition of mitochondrial proteome in health and disease. Briefly, my specific activity is to compare mitochondrial functional status with the mitochondrial proteome picture in different human cell line. I do think that a "contact" between these two important initiatives should be useful for both.
- Moreover, to stress the potential translational applications of research on bioenergetics in general and on mitochondria in particular (as also recently highlighted by Paolo Bernardi during EBEC 2016), I would like to suggest to begin to think to a careful pathophysiological classification of all mitochondriopathies (inborn and acquired, primary and secondary, ECR of metabolic related and so on) to reinforce the concept of a “mitochondrial medicine”, concept, until now, too often neglected with dramatic consequences. - Scatena Roberto (2016).